Skip to main content
    P

    Procept Biorobotics Corp (PRCT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $23.54
    -0.26 (-1.09%)

    Market Cap: $1.37B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Procept Biorobotics Corp (PRCT) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Procept Biorobotics (PRCT) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Procept Biorobotics reported EPS of -$0.46, below the -$0.39 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    50%(11/22)
    Avg Surprise
    -0.48%

    Upcoming Estimates

    Reports Feb 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.25
    Range-$0.27 - -$0.20
    17 analysts
    Revenue Consensus
    $120.40M
    Range$102.76M - $131.88M
    16 analysts
    Reports Apr 27, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.43
    Range-$0.52 - -$0.34
    11 analysts
    EPS Revisions
    1
    6
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.38-14.2%
    60d ago-$0.38-14.1%
    30d ago-$0.38-14.1%
    7d ago-$0.38-12.1%
    Current-$0.43
    Revenue Consensus
    $104.60M
    Range$101.40M - $108.20M
    10 analysts

    Next Report

    PRCT has an expected report date of Feb 23, 2027.

    PRCT Earnings Call

    The latest PRCT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 22 quarters below that had an estimate, PRCT beat 11, missed 9 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $98.29M, up 18.0% from $83.33M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.46-$0.39-$0.42 - -$0.34-17.95%MissN/A110 up, 9 downNov 4, 2026$98.29M
    Jun 30, 2026-$0.47-$0.46-$0.51 - -$0.36-2.17%MissN/A101 up, 1 downAug 4, 2026$94.50M
    Mar 31, 2026-$0.56-$0.56-$0.61 - -$0.480.00%In lineN/A100 up, 8 downApr 29, 2026$83.13M
    Dec 31, 2025-$0.53-$0.32-$0.35 - -$0.28-63.43%MissN/A90 up, 3 downFeb 25, 2026$76.38M
    Sep 30, 2025-$0.38-$0.42-$0.45 - -$0.38+9.52%BeatN/A91 up, 7 downNov 4, 2025$83.33M
    Jun 30, 2025-$0.35-$0.41-$0.49 - -$0.31+14.63%BeatN/A101 up, 0 downAug 6, 2025$79.18M
    Mar 31, 2025-$0.45-$0.49-$0.51 - -$0.47+8.16%BeatN/A80 up, 4 downApr 24, 2025$69.16M
    Dec 31, 2024-$0.35-$0.34-$0.44 - -$0.32-2.94%MissN/A82 up, 0 downFeb 25, 2025$68.24M
    Sep 30, 2024-$0.40-$0.49-$0.51 - -$0.44+18.37%BeatN/A71 up, 0 downOct 28, 2024$58.37M
    Jun 30, 2024-$0.50-$0.52-$0.55 - -$0.50+3.85%BeatN/A80 up, 0 downAug 1, 2024$53.35M
    Mar 31, 2024-$0.51-$0.56-$0.61 - -$0.49+8.93%BeatN/A80 up, 0 downMay 1, 2024$44.54M
    Dec 31, 2023-$0.54-$0.45-$0.50 - -$0.40-20.00%MissN/A80 up, 0 downFeb 27, 2024$43.58M
    Sep 30, 2023-$0.51-$0.52-$0.56 - -$0.51+1.92%BeatN/A90 up, 0 downNov 1, 2023$35.10M
    Jun 30, 2023-$0.56-$0.56-$0.62 - -$0.550.00%In lineN/A80 up, 0 downJul 27, 2023$33.10M
    Mar 31, 2023-$0.63-$0.58-$0.64 - -$0.54-8.62%MissN/A70 up, 1 downApr 27, 2023$24.40M
    Dec 31, 2022-$0.56-$0.54-$0.59 - -$0.50-3.70%MissN/A70 up, 0 downFeb 28, 2023$23.78M
    Sep 30, 2022-$0.51-$0.52-$0.53 - -$0.42+1.92%BeatN/A80 up, 0 downNov 3, 2022$20.35M
    Jun 30, 2022-$0.43-$0.48-$0.50 - -$0.45+10.42%BeatN/A50 up, 0 downAug 4, 2022$16.69M
    Mar 31, 2022-$0.39-$0.47-$0.52 - -$0.43+17.02%BeatN/A40 up, 0 downMay 5, 2022$14.20M
    Dec 31, 2021-$0.42-$0.39-$0.42 - -$0.37-7.69%MissN/A50 up, 0 downMar 8, 2022$10.14M
    Sep 30, 2021-$0.32-$0.42-$0.45 - -$0.34+23.81%BeatN/A4N/ANov 4, 2021$8.67M
    Jun 30, 2021-$0.41-$0.40N/A-2.50%MissN/AN/AN/ASep 16, 2021$8.48M
    Mar 31, 2021-$2.63N/AN/AN/AN/AN/AN/AN/AJun 30, 2021$7.19M
    Dec 31, 2020-$2.63N/AN/AN/AN/AN/AN/AN/AMar 31, 2021$3.22M
    Sep 30, 2020-$3.03N/AN/AN/AN/AN/AN/AN/ADec 31, 2020$2.11M
    Jun 30, 2020-$3.03N/AN/AN/AN/AN/AN/AN/ASep 30, 2020$1.19M
    Mar 31, 2020-$4.56N/AN/AN/AN/AN/AN/AN/AJun 29, 2020$1.19M
    Dec 31, 2019-$4.56N/AN/AN/AN/AN/AN/AN/AMar 30, 2020N/A
    Last 28 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.71, after -$1.76 the year before. It was -$4.56 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.71N/A
    Dec 31, 2024-$1.76N/A
    Dec 31, 2023-$2.24N/A
    Dec 31, 2022-$1.89N/A
    Dec 31, 2021-$3.78N/A
    Dec 31, 2020-$13.24N/A
    Dec 31, 2019-$4.56N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,400 words across 17 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,42117
    2026Q2Jun 30, 20268,28816
    2026Q1Mar 31, 20265,89015
    2025Q4Dec 31, 20258,56816
    2025Q3Sep 30, 20258,03717
    2025Q2Jun 30, 20257,93616
    2025Q1Mar 31, 20258,67816
    2024Q4Dec 31, 20249,35114

    2026Q3 Earnings Call

    Opening remarks

    Webb Campbell Gilmartin Group Good afternoon, and thank you for joining PROCEPT BioRobotics Third Quarter 2026 Earnings Conference Call. Presenting on today's call are Larry Wood, Chief Executive Officer, and Kevin Waters, Chief Financial Officer. Before we begin, I'd like to remind listeners that statements made on this conference call that relate to future plans, events or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. While these forward-looking statements are based on management's current expectations and beliefs, these statements are subject to several risks and uncertainties, assumptions and other factors that could cause results to differ materially from the expectations expressed on this conference call. These risks and uncertainties are disclosed in more detail in PROCEPT BioRobotics' filings with the Securities and Exchange Commission, all of which are available online at sec.gov. Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date, November 4, 2026. Except as required by law, PROCEPT BioRobotics undertakes no obligation to update or revise any forward-looking statements to reflect new information, circumstances or unanticipated events that may arise. During the call, we'll also reference certain financial measures that are not prepared in accordance with GAAP. More information about how we use these non-GAAP financial measures, as well as reconciliations of these measures to their nearest GAAP equivalents, are included in our earnings release. With that, I'd like to turn the call over to Larry.

    Larry Wood CEO Good afternoon, and thank you for joining us. This quarter, we continued to execute against the priorities we set at the beginning of the year and delivered total revenue of $98.3 million, reflecting 18% year-over-year growth. We completed over 13,400 U.S. procedures in the quarter, growing 22% year-over-year, led by our HYDROS accounts, where we continue to see strong utilization. With our installed base actively transitioning to HYDROS and our dedicated launch team supporting new systems, we continue to strengthen our foundation for healthy utilization and growth. U.S. handpiece and consumable revenue grew over 21%, with handpieces sold at 106% of procedures, roughly consistent with our full-year projections of a 1:1 ratio and reflecting normalized field inventory. Handpiece pricing remained strong at approximately $3,570, reflecting our continued price discipline. Turning to U.S. systems, we placed 62 HYDROS systems in the quarter, including 20 replacement systems. We continue to accelerate the upgrade of legacy AQUABEAM systems to HYDROS. While the greenfield placements fell short of our expectations for Q3, this was largely a function of timing, and we are seeing healthy overall capital demand continue into the fourth quarter.

    Frequently Asked Questions About PRCT

    When is Procept Biorobotics's next earnings date?

    Procept Biorobotics's next earnings report is expected for Feb 23, 2027.

    Did PRCT beat earnings estimates last quarter?

    No. Procept Biorobotics reported EPS of -$0.46 for the quarter ended Sep 30, 2026, below the -$0.39 estimate by 17.95%.

    What EPS do analysts expect from PRCT next quarter?

    The consensus EPS estimate for Procept Biorobotics for the quarter ending Dec 31, 2026 is -$0.25 from 17 analysts, with estimates from -$0.27 to -$0.20.

    How often does PRCT beat earnings estimates?

    Procept Biorobotics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -6.77%.